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By Masayuki AMAGAI*1,†
(Communicated by Kimishige ISHIZAKA, M.J.A.)
Abstract: Desmosomes are intercellular adhesive junctions of epithelial cells that contain
two major transmembrane components, the desmogleins (Dsg) and desmocollins (Dsc), which are
cadherin-type cell–cell adhesion molecules and are anchored to intermediate ﬁlaments of keratin
through interactions with plakoglobin and desmoplakin. Desmosomes play an important role in
maintaining the proper structure and barrier function of the epidermis and mucous epithelia. Four
Dsg isoforms have been identiﬁed to date, Dsg1–Dsg4, and are involved in several skin and heart
diseases. Dsg1 and Dsg3 are the two major Dsg isoforms in the skin and mucous membranes, and are
targeted by IgG autoantibodies in pemphigus, an autoimmune disease of the skin and mucous
membranes. Dsg1 is also targeted by exfoliative toxin (ET) released by Staphylococcus aureus in the
infectious skin diseases bullous impetigo and staphylococcal scalded skin syndrome (SSSS). ET is a
unique serine protease that shows lock and key speciﬁcity to Dsg1. Dsg2 is expressed in all tissues
possessing desmosomes, including simple epithelia and myocardia, and mutations in this gene
are responsible for arrhythmogenic right ventricular cardiomyopathy/dysplasia. Dsg4 plays an
important adhesive role mainly in hair follicles, and Dsg4 mutations cause abnormal hair
development. Recently, an active disease model for pemphigus was generated by a unique approach
using autoantigen-deﬁcient mice that do not acquire tolerance against the defective autoantigen.
Adoptive transfer of Dsg3−/− lymphocytes into mice expressing Dsg3 induces stable anti-Dsg3 IgG
production with development of the pemphigus phenotype. This mouse model is a valuable tool with
which to investigate immunological mechanisms of harmful IgG autoantibody production
in pemphigus. Further investigation of desmoglein molecules will continue to provide insight into
the unsolved pathophysiological mechanisms of diseases and aid in the development of novel
therapeutic strategies with minimal side eﬀects.
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What is pemphigus?
The term pemphigus stems from the Greek
pemphix, meaning blister or bubble, and describes a
group of chronic blistering skin diseases in which
autoantibodies are directed against the cell surface
of keratinocytes, resulting in the loss of cell–cell
adhesion of keratinocytes through a process called
acantholysis. In 1964, Beutner and Jordon discovered
that sera from patients with pemphigus contain
circulating IgG autoantibodies directed against the
cell surface of keratinocytes.1) The modern history of
pemphigus as an autoimmune disease began with this
ﬁnding (Fig. 1). In the late 1970s to early 1980s,
pemphigus autoantibodies were shown to have
pathogenic activity in the induction of blister
formation in skin organ culture systems as well as
by passive transfer of patients’ IgG into neonatal
mice.2),3) In the mid- to late 1980s, the target antigens
of pemphigus were characterized by immunochemical
methods, such as immunoprecipitation and immuno-
blotting.4),5) In the early 1990s, isolation of cDNA for
pemphigus antigens demonstrated that the target
antigens in pemphigus are desmogleins.6),7)
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Pemphigus has three major forms: pemphigus
vulgaris, pemphigus foliaceus, and paraneoplastic
pemphigus. The hallmark of pemphigus is the ﬁnding
of IgG autoantibodies against the keratinocyte cell
surface.
1. Pemphigus vulgaris. All patients with
pemphigus vulgaris show mucous membrane lesions,
which are usually seen as painful erosions (Fig. 2A).
Intact blisters are rare, probably because they are
fragile and break easily. Extensive erosions and
painful lesions in the mouth may result in decreased
food and drink intake. Involvement of the throat may
produce hoarseness and diﬃculty in swallowing. The
esophagus, conjunctiva, nasal mucosa, vagina, penis,
anus, and labia may also be involved. The diagnosis
of pemphigus vulgaris tends to be delayed in patients
presenting with only oral involvement in comparison
to those with skin lesions.
The primary skin lesions of pemphigus vulgaris
are ﬂaccid, thin-walled, easily ruptured blisters that
appear anywhere on the skin surface (Fig. 2C). The
blisters arise on normal-appearing skin or erythem-
atous bases. The blisters are fragile and soon rupture
to form painful erosions that ooze and bleed easily.
Without appropriate treatment, pemphigus vulgaris
can be fatal because large areas of the skin lose
epidermal barrier function, leading to loss of body
ﬂuids or secondary bacterial infection.
2. Pemphigus foliaceus. Patients with
pemphigus foliaceus develop scaly, crusted erosions,
often on an erythematous base in the skin, but do
not have apparent mucous-membrane involvement,
even with widespread disease (Fig. 2D). The onset
of disease is often subtle, with a few scattered
Fig. 1. History of pemphigus research. In 1964 Beutner and Jordon discovered that patients with pemphigus have IgG autoantibodies
against keratinocytes. In 1991, their target antigens were discovered to be desmogleins (Dsg1 and Dsg3), cadherin-type cell–cell adhesion
molecules in desmosomes. Further studies will reveal how T cells and B cells begin to produce harmful autoantibodies in pemphigus
patients.
Fig. 2. Clinical pictures of pemphigus patients. A. Oral erosions in a patient with pemphigus vulgaris. B. Heavily clotted and crusted
lesions around the mouth in a patient with paraneoplastic pemphigus. C. Skin lesions found on the trunk in a patient with pemphigus
vulgaris. D. Skin lesions on the trunk in a patient with pemphigus foliaceus.
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misdiagnosed as impetigo. These lesions are usually
well demarcated and scattered in a seborrheic
distribution, including the face, scalp, and upper
trunk. The disease may remain localized for years or
may progress rapidly, in some cases to generalized
involvement resulting in erythrodermic exfoliative
dermatitis.
3. Paraneoplastic pemphigus. Paraneoplastic
pemphigus is a recently described form of pemphigus
that occurs in association with underlying neo-
plasms.8),9) Paraneoplastic pemphigus is unique and
distinct from the classic forms of pemphigus vulgaris
and foliaceus based on clinical, histological, and
immunopathological criteria. The most constant
clinical feature of paraneoplastic pemphigus is the
presence of intractable stomatitis (Fig. 2B). The
severe stomatitis is usually the earliest presenting
sign; it is also the one that persists after treat-
ment and is extremely resistant to therapy. This
stomatitis consists of erosions and ulcerations that
aﬀect all surfaces of the oropharynx and character-
istically extend onto the vermillion of the lip. Most
patients also have severe pseudomembranous con-
junctivitis with scarring. The cutaneous lesions are
quite polymorphic and may appear as erythematous
macules, ﬂaccid blisters and erosions, tense blisters,
erythema multiforme-like lesions, and lichenoid
eruptions. Extensive cases show clinical resemblance
to toxic epidermal necrolysis (TEN).
Paraneoplastic pemphigus is the only form of
pemphigus that shows involvement of nonstratiﬁed
squamous epithelia. Approximately, 30–40% of
patients develop pulmonary symptoms.10),11) The
earliest symptoms are progressive dyspnea, and
pulmonary function studies show airﬂow obstruction
involving large and small airways, as seen in
bronchiolitis obliterans, which can be fatal through
respiratory failure.
Pemphigus is mediated by IgG autoantibodies
against desmogleins
Molecular cloning of cDNA encoding pemphigus
antigens has indicated that IgG autoantibodies from
patients recognize desmogleins (Dsg), which are
cadherin-type cell–cell adhesion molecules found in
the adhering junctions, the desmosomes6),7) (Fig. 3).
Cadherins are a family of calcium-dependent cell–cell
adhesion molecules that play important roles in the
formation and maintenance of complex tissue integ-
rity.12) The cadherins are divided into two major
subgroups based on sequence similarity, i.e., the
classic cadherins (e.g., E-, P-, N-cadherins) and the
desmosomal cadherins (desmogleins and desmocol-
lins). All members of the cadherin family contain
conserved repeated amino-acid sequences (cadherin
repeats) with calcium-binding motifs in their extra-
cellular domains. When classic cadherins were
introduced by gene transfection into nonadhesive
mouse ﬁbroblast L cells, the cells acquired strong cell
Fig. 3. Molecular structure of the pemphigus antigens. The extracellular (EC) region has four cadherin repeats, which have calcium-
binding motifs. The intracellular cadherin-speciﬁc (ICS) domain is well conserved among cadherins and is responsible for interactions
with --catenin and plakoglobin. Desmogleins have their own unique sequences (repeating unit domain or RUD) of repeats of 29 ± 1
residues (arrowheads). Each desmocollin isotype has two products (a and b) derived from alternatively spliced transcripts of a single
gene. Boxes with the same color have similarities in their amino acid sequences. IA, intracellular anchor domain; IPL, intracellular
proline-rich linker; DTD, desmoglein-speciﬁc terminal domain.
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fection with diﬀerent cadherins, cells expressing
identical cadherin types bound to each other,
indicating that the classic cadherins mediate homo-
philic-type interactions.14) Cadherins require their
well-conserved cytoplasmic domains to associate with
plaque proteins, ,-catenin, --catenin, and plakoglo-
bin, which mediate and regulate binding to the
cytoskeleton network. As a consequence of these
interactions, cadherins achieve strong cell–cell adhe-
sion with resultant morphological changes of the
cells. In contrast, calcium-independent cell adhesion
molecules, such as the immunoglobulin superfamily,
mediate simple molecular interactions and do not
involve morphological changes of cells. The “cell
adhesion zipper” model has been proposed as a
structural basis of cell adhesion mediated by classic
cadherins.15) Cadherin molecules form a dimer as a
functional unit, and each individual strand dimer
interacts with opposing strand dimers on another cell
through an adhesion interface of the N-terminal
domain (EC1).
Based on morphological and biochemical crite-
ria, there are two major types of adhering junctions
in epithelial cells: adherens junctions and desmo-
somes.16),17) Adherens junctions anchor bundles of
actin microﬁlaments and contain classic cadherins as
transmembrane components and ,-catenin, --cate-
nin, and plakoglobin as cytoplasmic components,
while desmosomes anchor intermediate ﬁlaments
such as keratins and contain desmosomal cadherins
as transmembrane components and plakoglobin,
plakophilin, and desmoplakin as cytoplasmic compo-
nents. In general, adherens junctions mediate rapid
but weak cell adhesion, while desmosomes mediate
slow but strong cell adhesion. The establishment of
adherens junctions is a prerequisite for desmosomal
assembly in keratinocytes.18)
Desmogleins have four cadherin repeats in their
extracellular domain, as do classic cadherins, and
have an extra carboxy-terminal domain containing
repeats of 29 ± 1 residues (Fig. 3). There are four
desmoglein isoforms, designated Dsg1–4. Expression
of desmoglein 1 and 3 is restricted to stratiﬁed
squamous epithelia where blisters are formed in
pemphigus, while desmoglein 2 is expressed in all
tissues possessing desmosomes, including simple
epithelia and myocardia.19) Dsg4 plays an important
adhesive role primarily in hair follicles.20) Desmocol-
lins are another transmembrane glycoprotein of the
desmosomes and exist in three isoforms, Dsc1–3.
Each isoform has two products derived from alter-
natively spliced mRNA of a single gene. Desmosomes
always have desmoglein and desmocollin as a pair,
but the precise nature of their interaction remains to
be elucidated at the molecular level. Pemphigus
foliaceus and vulgaris antigens are now called Dsg1
and Dsg3, respectively. Thus, pemphigus is an anti-
desmoglein autoimmune disease. The basic patho-
physiology of pemphigus is that autoantibodies
inhibit the adhesive function of desmogleins and lead
to loss of cell–cell adhesion of keratinocytes with
resultant blister formation.
There is compelling evidence that IgG autoanti-
bodies against Dsg1 and Dsg3 are pathogenic and
play a primary role in blister formation in pemphigus.
When monitored in individual patients, the titers of
serum anti-Dsg1 and anti-Dsg3 IgG autoantibodies,
as determined by indirect immunoﬂuorescence or
ELISA, are generally correlated with disease activ-
ity.21),22) Aﬃnity-puriﬁed IgG from pemphigus vul-
garis sera on the extracellular domain of Dsg3 can
cause suprabasilar acantholysis, a typical histological
ﬁnding of pemphigus vulgaris, when injected into
neonatal mice.23) Furthermore, when anti-Dsg3 IgG
is immunoadsorbed with the extracellular domains of
Dsg3 from pemphigus vulgaris sera, these sera no
longer have pathogenic activity to cause blisters in
neonatal mice.24) Similarly, immunoadsorption of
pemphigus foliaceus sera with the extracellular
domain of Dsg1 eliminates the pathogenic activity
of these sera and anti-Dsg1 IgG bound on the column
caused superﬁcial blisters in neonatal mice.25) Finally,
monoclonal antibodies against desmogleins from
pemphigus model mice and patients induce blisters
that are histologically similar to those seen in
patients.26),27)
Desmoglein ELISA as a useful diagnostic
tool for pemphigus
With a diagnosis of suspected pemphigus based
on clinical ﬁndings, it is important to perform serum
tests to identify IgG autoantibodies against cell-
surface antigens of keratinocytes or desmogleins.
In the diagnosis of pemphigus, ELISA provides a
speciﬁc, sensitive, and quantitative means of detect-
ing and measuring circulating IgG autoantibod-
ies.28),29) The patient’s serum is tested on ELISA
plates precoated with recombinant Dsg1 or Dsg3
proteins produced in the baculovirus expression
system. ELISA enables us to serologically distinguish
subtypes of pemphigus vulgaris and foliaceus
(Fig. 4). In general, if serum is positive against
Dsg1 but negative against Dsg3, this suggests a
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negative against Dsg1 but positive against Dsg3
suggests a diagnosis of mucosal-dominant-type pem-
phigus vulgaris. Serum positivity against both Dsg1
and Dsg3 suggests a diagnosis of mucocutaneous-
type pemphigus vulgaris. Furthermore, ELISA scores
show parallel ﬂuctuation with disease activity.22)
Thus, ELISA is also useful for monitoring disease
activity to plan tapering schedules of corticosteroids
and to predict ﬂares or relapses before clinical
evidence is noted.
Logical explanation for the site of blister
formation in pemphigus
Although the disruption of desmoglein-depend-
ent cell adhesion by autoantibodies is the basic
pathophysiology underlying blister formation in
pemphigus, the clinical spectrum is more complex.
This complex clinical feature of pemphigus is now
logically explained by the desmoglein compensation
theory: Dsg1 and Dsg3 compensate for each other
when coexpressed in the same cell.30),31)
The intraepithelial expression patterns of Dsg1
and Dsg3 in skin and mucous membranes diﬀer. In
the skin, Dsg1 is expressed throughout the epidermis,
but more intensely in the superﬁcial layers, while
Dsg3 is expressed in the lower portion of the
epidermis, primarily in the basal and parabasal
layers. In contrast, Dsg1 and Dsg3 are expressed
throughout the squamous layer of the mucosa, but
the former is expressed at a much lower level than the
latter.
When sera contain only anti-Dsg1 IgG, which
interferes with the function of Dsg1, the presence of
Dsg3 compensates for the loss of function of Dsg1
in the lower epidermis. In contrast, in the upper
epidermis, there is no compensation by Dsg3. There-
fore, blisters appear only in the superﬁcial epidermis
of the skin. Although anti-Dsg1 IgG binds to the
mucosa, no blisters are formed because of the
coexpression of Dsg3. Thus, sera containing only
anti-Dsg1 IgG cause superﬁcial blisters in the skin
without mucosal involvement, as seen in patients
with pemphigus foliaceus. Sera containing only anti-
Dsg3 IgG do not eﬀectively cause blisters in the skin
because the coexpressed Dsg1 compensates for the
impaired function of Dsg3, resulting in no or only
limited skin blisters. In contrast, in mucous mem-
branes, Dsg1 cannot compensate for the impaired
Dsg3 function due to its low level of expression.
Therefore, sera containing only anti-Dsg3 IgG cause
oral erosions without apparent skin involvement, as
seen in patients with mucosal-dominant-type pem-
phigus vulgaris. When sera contain both anti-Dsg1
and anti-Dsg3 IgG, they interfere with the functions
of both Dsg1 and Dsg3, resulting in extensive blisters
and erosions in the skin as well as the mucous
membranes, as seen in patients with mucocutaneous-
type pemphigus vulgaris.
What is bullous impetigo and staphylococcal
scalded skin syndrome (SSSS)?
Impetigo is a common and highly contagious
superﬁcial skin infection that primarily aﬀects
Fig. 4. Serological diagnosis of pemphigus with ELISA. Patients with pemphigus foliaceus (PF) have only anti-Dsg1 IgG autoantibodies,
but not anti-Dsg3 IgG autoantibodies. Patients with mucosal dominant-type pemphigus vulgaris (PV) have only anti-Dsg3 IgG
autoantibodies, but not anti-Dsg1 IgG autoantibodies. PV patients with mucocutaneous lesions have both anti-Dsg1 and anti-Dsg3
IgG autoantibodies. Normal individuals do not have any IgG autoantibodies against Dsg1 or Dsg3.
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bullous types, and bullous impetigo is caused by S.
aureus. Staphylococcal scalded skin syndrome (SSSS)
is a generalized form of bullous impetigo that most
commonly aﬀects children under 6 years of age,
particularly neonates, and can occasionally aﬀect
adults with chronic renal insuﬃciency or immuno-
suppression. The blisters in bullous impetigo and
SSSS are induced by exfoliative toxin (ET) released
by S. aureus.32) In bullous impetigo, the toxin
produces blisters locally at the site of infection; in
SSSS, S. aureus is present in the pharynx, nose, ear,
or conjunctiva, and the ET circulates throughout the
body, causing blisters at sites distant from the
infection.
Clinically, bullous impetigo commonly begins on
any part of the body as small vesicles that enlarge
rapidly into superﬁcial ﬂaccid bullae ﬁlled with
cloudy ﬂuid surrounded by an erythematous rim
(Fig. 5A). These bullae rupture easily, leaving shiny
erosions with scaly crusts. SSSS begins as erythema,
frequently with a prodrome of malaise, low-grade
fever, irritability, and tenderness of the skin. The
rash progresses to a characteristic wet-tissue-paper-
like wrinkling due to the formation of ﬂaccid blisters
within 24 to 48h (Fig. 5B). Subsequent generalized
involvement elsewhere on the body occurs, but spares
the mucous membranes. Histologically, both bullous
impetigo and SSSS are characterized by intraepider-
mal cleavage in the upper layers of the epidermis, i.e.,
beneath or within the granular layers. In SSSS, the
remainder of the epidermis appears unremarkable
without keratinocyte necrosis and the dermis con-
tains no inﬂammatory cell inﬁltrates in the fresh
lesions. In bullous impetigo, however, the blister
cavities become ﬁlled with neutrophils and the
underlying dermis contains mixed inﬁltrates of
neutrophils and lymphocytes in response to the
inﬂammatory reaction to S. aureus.
ETs are Dsg1-speciﬁc serine-proteases
The pathogenic role of ET was ﬁrst demon-
strated by injecting ET into neonatal mice, which
developed extensive skin blisters with the typical
histology of superﬁcial blister formation in the
granular layers as observed in patients (Fig. 5C,
D). It was realized that SSSS and pemphigus
foliaceus share many similar features. Both diseases
involve only the skin, and not mucous membranes or
other tissues. The histology of both diseases shows
superﬁcial epidermal separation where Dsg3 is not
coexpressed. Pathology textbooks actually note that
the histology of both diseases is indistinguishable.
Neonatal mice injected with IgG from pemphigus
Fig. 5. Bullous impetigo and staphylococcal scalded skin syndrome in humans and mice. A. Patients with bullous impetigo develop
superﬁcial ﬂaccid blisters and shiny erosions with scaly crusts. B. Patients with staphylococcal scalded skin syndrome show wide-
spread erosions with characteristic wet-tissue-paper-like wrinkling due to the formation of ﬂaccid blisters. C. Neonatal mice injected
with staphylococcal exfoliative toxin develop extensive superﬁcial blisters with a wet-tissue-paper-like wrinkled appearance. D.
Histology of the mice shows acantholysis due to loss of cell–cell adhesion in the upper layers of the epidermis. The bar indicates 50µm.
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identical histology (Fig. 5C, D). These similarities
suggested that the molecular mechanism of blister
formation in SSSS is similar to that in PF, and we
began to investigate the changes in Dsg1 levels after
ET treatment.33)
We ﬁrst stained for Dsg1 and Dsg3 in the skin
1h after injecting ETA into neonatal mice. ETA
caused substantial changes in Dsg1 staining, which
was much less intense on keratinocyte cell surfaces,
while there were no apparent changes in Dsg3
staining. To demonstrate direct proteolysis of the
extracellular domain of Dsg1 by ETA, we then
incubated soluble recombinant forms of the extra-
cellular domains of Dsg1 and Dsg3 with ETA in vitro.
ETA cleaved the recombinant mouse and human
Dsg1 in a dose-dependent manner, while ETA did not
cleave Dsg3. Taken together, these ﬁndings indicate
that ETA speciﬁcally recognizes and cleaves the
extracellular domains of both mouse and human
Dsg1. Other serotypes of ET, ETB and ETD, were
also shown to speciﬁcally cleave Dsg1 in a manner
identical to ETA.34),35) Identiﬁcation of the physio-
logical substrate of ET also conﬁrmed the function of
ET as a trypsin-like serine protease as predicted by
structural analysis.36)–38)
When ET reaches the skin and digests Dsg1 in
the lower layers of the epidermis, Dsg3 compensates
for the loss of function of Dsg1 and manages to
maintain cell–cell adhesion, while no compensation
by Dsg3 occurs in the superﬁcial layers of the
epidermis. Therefore, ET induces superﬁcial blisters
on the skin. In mucous membranes, the Dsg3
expressed throughout the squamous layers of the
mucosa compensates for the impaired Dsg1 and
maintains cell–cell adhesion with no mucosal
involvement.39) These dermatological ﬁndings on
the clinical and histological pictures provide an
important framework to understand the molecular
mechanisms of blister formation in these diseases, as
well as cell–cell adhesion of keratinocytes in the
epidermis.
Autoimmune reaction to digested Dsg1
in patients with SSSS
In the pathophysiology of autoimmune disease,
triggering of the immune response has been suggested
to involve molecular mimicry. In such cases, the
antibodies that are produced against the infectious
agent are thought to coincidentally crossreact with
normal tissues. The observation that an antibody-
mediated tissue-speciﬁc autoimmune disease, pem-
phigus foliaceus, and two related infectious diseases,
bullous impetigo and SSSS, target the same molecule,
Dsg1, also indicates that autoimmunity and infection
are connected through Dsg1. These ﬁndings suggest
that a bacterial toxin may bind to and partially
degrade a self-antigen, with the modiﬁed self-antigen
triggering the immune response.
When paired serum samples were examined from
30 patients with SSSS, 6 of 30 (20.0%) cases with
SSSS developed low titers of anti-Dsg1 IgG autoanti-
bodies as detected by ELISA (4/30) or immunoblot-
ting analysis (4/30), although none developed any
detectable anti-Dsg3 IgG antibodies.40) Although it
was diﬃcult to obtain paired sera because most of the
patients were infants or small children, four patients
with SSSS showed a shift from negative to positive
anti-Dsg1 IgG. No apparent IgM reactivity against
Dsg1 or Dsg3 was detected by ELISA. None of 12
patients with bullous impetigo, a localized form
of SSSS, showed any detectable IgG production
against Dsg1 or Dsg3, as determined by ELISA and
immunoblotting.
These ﬁndings indicate that a small number of
SSSS patients develop low titers of IgG antibodies
speciﬁc for Dsg1 after binding and systemic digestion
of Dsg1 by staphylococcal ETs. Although none of
these patients developed pemphigus foliaceus after
SSSS, which is not known as a predisposing factor for
pemphigus foliaceus, the ﬁndings presented here
provide evidence that infections that modify self
antigens can trigger the production of IgG autoanti-
bodies against the self antigen. The relevance of this
ﬁnding to onset of autoimmune diseases remains to
be conﬁrmed.
Pathogenic anti-desmoglein IgG autoantibodies
preferentially attack the most functionally
important part of the molecule
Characterization of the Dsg binding sites of the
pathogenic pemphigus autoantibodies is an essential
step in understanding the pathophysiology of blister
formation in pemphigus, as well as the basic molecu-
lar mechanism of Dsg-mediated cell–cell adhesion.
This characterization is hindered by the fact that
binding of autoantibodies to Dsgs is dependent not
only on amino acid sequence but also on molecular
conformation. This dependence on molecular con-
formation is shown by the observation that recombi-
nant Dsg1 and Dsg3, when expressed in baculovirus
as secreted proteins, immunoadsorb heterogeneous
autoantibodies from the sera of pemphigus foliaceus
and pemphigus vulgaris patients, and that this
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by Ca2+-chelation, acid or alkaline treatment, or
boiling. Therefore, a conventional approach using
variously truncated Dsg molecules is inappropriate
for deﬁnition of the conformational epitopes of Dsgs
in pemphigus. Therefore, a strategy based on domain
swapping and point mutations was chosen to map
regions within Dsg1 and Dsg3 that constitute the
conformational epitopes. In both pemphigus vulgaris
and foliaceus patients, major epitopes were mapped
to the respective N-terminal 161 residues of Dsg1 and
Dsg3.41) These N-terminal 161 residues contained
critical epitopes recognized by pathogenic IgG anti-
bodies because the immunoadsorption of pemphigus
foliaceus sera with residues 1–161 of Dsg1 blocked
their ability to induce blisters in neonatal mice. A
pathogenic monoclonal antibody isolated from the
adoptive transfer mouse model of pemphigus has
been shown to recognize a speciﬁc calcium-dependent
conformational epitope within the desmoglein adhe-
sive interface, while nonpathogenic anti-Dsg anti-
bodies map to a more carboxy-terminal extracellular
domain.26),42) Recently, using antibody phage dis-
play, repertoires of human anti-Dsg monoclonal
antibodies (mAbs) as single chain variable region
fragments (scFv) were isolated from patients with
pemphigus vulgaris and foliaceus.27),43) The isolated
scFvs contained both pathogenic and nonpathogenic
antibodies as determined by in vitro dissociation
assay and passive transfer assay using neonatal mice.
The pathogenic scFvs recognized the N-terminal
domains of Dsg1 and Dsg3.
Recent high-resolution crystal structure analyses
of classic cadherins have provided a mechanistic basis
for intermolecular cadherin interactions.44) This
structure provides a new framework for understand-
ing both the cis (same cell) and trans (juxtaposed
cell) interactions of cadherin. The trans adhesive
interface is a twofold symmetrical interaction that is
deﬁned by a conserved tryptophan (W2) side chain
at the amino-terminal, membrane-distal end of the
cadherin molecule from one cell, which inserts into
the hydrophobic pocket at the amino-terminal end of
a cadherin molecule on an opposing cell. This simple
twofold symmetry provides a rationale for the
generally observed homophilic speciﬁcity of cadher-
ins, and reveals the molecular determinants of
cadherin speciﬁcity. Taken together, the structural
bases of classic cadherins and the results of the above
epitope map studies indicate that the pathogenic
autoantibodies in pemphigus are dominantly raised
against the N-terminal adhesive interfaces of Dsg1
and Dsg3, which are the functionally important parts
of the molecules.
A novel autoimmune mouse model using
mice deﬁcient for the autoantigen
To investigate the pathophysiological mecha-
nisms and develop therapeutic strategies, animal
disease models have played important roles in the
study of various conditions, including autoimmune
diseases. The conventional approach to develop an
autoimmune mouse model is forced immunization of
autoantigens in various strains of mice with various
types of adjuvant (Fig. 6A). However, this approach
is empirical and immune responses are largely
dependent on the strain of mouse or type of adjuvant
used. Furthermore, any autoimmune reaction in these
mice may be transient, unlike that found in patients,
and the immune system is systemically stimulated.
The major obstacle in the development of an
autoimmune reaction in mice is self-tolerance, which
prevents the immune system from reacting destruc-
tively against components of the living body. When
lymphocytes are exposed to autocomponents during
the development of the immune system, auto-
reacting lymphocytes are eliminated or inacti-
vated.45),46) We have taken a novel approach to
overcome this obstacle. As self-tolerance is a techni-
cal barrier to the development of autoimmune mouse
models, we attempted to generate conditions where
self-tolerance is not established in an antigen-speciﬁc
manner (Fig. 6B). If it were possible to remove the
antigen during the development of the immune
system, or if it were not present from the start,
tolerance against the removed or absent molecule
would not be acquired.42) In autoantigen knockout
mice, lymphocytes are not exposed to the defective
gene product, and self-tolerance against that partic-
ular autoantigen is not established. Upon immuniza-
tion with the autoantigen, the autoantigen knockout
mice should elicit an immune reaction against the
autoantigen. However, in the immunized knockout
mice, no antigen–antibody reaction is expected
because the mice lack the target antigen. Therefore,
lymphocytes from the immunized autoantigen knock-
out mice are adoptively transferred into immunode-
ﬁcient mice that express the autoantigen. The
transferred lymphocytes from the autoantigen knock-
out mice should be persistently stimulated by the
endogenous autoantigen in the recipient mice and
should therefore produce antibodies against the
autoantigen with resultant phenotypes of the human
disease.
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(immunodeficient mouse)
Dsg3-/-mouse
(no tolerance to Dsg3)
adoptive transfer of
peripheral T and B lymphocytes
wild type mouse
(tolerance to Dsg3)
A. Conventional way by repeated immunization
B. A novel approach by adoptive transfer of autoantigen-knockout lymphocytes
Dsg3
Fig. 6. Methods to develop an active disease mouse model for pemphigus vulgaris. In the conventional approach (A), various strains of
wild-type mice are repeatedly immunized with recombinant Dsg3 (rDsg3) in various adjuvants to break their immunological
tolerance. None of the immunized mice developed IgG that could bind to the native Dsg3 in vivo and showed no IgG deposition on
keratinocyte cell surfaces in the skin. In a novel approach (B), splenocytes of Dsg3−/− mice, which do not acquire tolerance against
Dsg3, were adoptively transferred into immunodeﬁcient mice expressing Dsg3. Recipient mice persistently produced anti-Dsg3 IgG
and developed the pemphigus vulgaris phenotype.
Fig. 7. Phenotype of the active disease model mice for pemphigus vulgaris. A. The recipient mice with Dsg3−/− splenocytes (upper) were
smaller than controls with Dsg3+/− splenocytes (lower) because oral erosions inhibited food intake. B. Some recipient mice with
Dsg3−/− splenocytes showed crusted erosions on the paws, where constant pressure is applied. C, D. Recipient mice with Dsg3−/−
splenocytes showed in vivo mouse IgG deposition on keratinocyte cell surfaces (C) and suprabasilar acantholysis (D) as observed in
patients with pemphigus vulgaris.
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We used this novel approach of using autoan-
tigen knockout mice to develop an active disease
model for pemphigus vulgaris in mice, in this case,
Dsg3−/− mice.42),47) When we immunized Dsg3−/−
mice with mouse recombinant Dsg3, anti-Dsg3 IgG
was indeed produced. These sera were able to bind to
the cell surfaces of living cultured mouse keratino-
cytes, indicating that the anti-Dsg3 IgG produced
in Dsg3−/− mice is capable of binding to the native
Dsg3 on living keratinocytes. In contrast, sera from
Dsg3+/− littermates or wild-type controls failed to
bind to the surface of living keratinocytes. These
ﬁndings conﬁrmed that Dsg3−/− mice and those
expressing Dsg3 have clear diﬀerences in their ability
to produce anti-Dsg3 IgG that can bind to the native
Dsg3.42)
Despite the production of anti-Dsg3 IgG, no
autoimmune reaction is expected in the immunized
Dsg3−/− mice because they lack the target antigen.
To allow the anti-Dsg3 IgG to be exposed to
the antigen, we isolated splenocytes from the immu-
nized Dsg3−/− mice and transferred them into
Rag-2−/− immunodeﬁcient mice that do express
Dsg3 (Fig. 6B). Rag-2−/− mice have no mature T
or B cells due to the inability to rearrange T cell
receptors or immunoglobulin genes and are therefore
unable to produce antibodies or reject transferred
splenocytes. Circulating anti-Dsg3 IgG was detected
in the sera of recipient Rag-2−/− mice as early as day
4 after transfer of Dsg3−/− splenocytes, and its titer
increased rapidly without further boosting by re-
combinant Dsg3, reaching a plateau around day 21.
The circulating anti-Dsg3 IgG was detected for as
long as 6 months. No signiﬁcant reactivity against
Dsg1 was observed in these recipient mice during this
period. In contrast, no circulating anti-Dsg3 IgG was
detected in Rag-2−/− mice given Dsg3+/− spleno-
cytes. The persistent anti-Dsg3 IgG production
indicates that endogenous Dsg3 in the recipient mice
stimulated the transferred Dsg3-speciﬁc lymphocytes
from the immunized Dsg3−/− mice in vivo.
In recipient mice with Dsg3−/− splenocytes, in
vivo IgG deposition was found on keratinocyte cell
surfaces in stratiﬁed squamous epithelia, including
the skin and oral and esophageal mucous membranes,
as seen in patients with pemphigus vulgaris
(Fig. 7C). In these mice, no IgG deposition was
found in other tissues, including heart, lung, liver,
kidney, stomach, and the small and large intestine.
These IgG binding sites correspond to the known
tissue distribution of Dsg3. Histological examination
of the recipient mice revealed intraepithelial loss of
cell–cell adhesion just above the basal layers, i.e.,
suprabasilar acantholysis, in the buccal mucosa, hard
palate, oropharyngeal areas, and the upper part of
the esophagus, as seen in human patients (Fig. 7D).
These oral erosions likely inhibited food intake,
resulting in weight loss (Fig. 7A). Some of the
recipient mice developed crusted erosions on the skin
around the snout, an area that is normally trauma-
tized by scratching, or paws, where constant pressure
is applied (Fig. 7B). Close histological examination
revealed that the recipient mice with Dsg3−/−
splenocytes also exhibited eosinophilic spongiosis,
which is often found in patients with early lesions.48)
We also observed patchy hair loss in the recipient
mice with Dsg3−/− splenocytes (Fig. 7A). Skin
biopsy showed intense IgG deposition on the cell
surface of keratinocytes surrounding the telogen hair
club. Cleft formation was observed between the cells
surrounding the telogen club and the basal layer of
the outer root sheath epithelium. In contrast, no
phenotypic or pathological changes were observed in
recipient mice with Dsg3+/− splenocytes.
These results indicate that the Rag-2−/− recip-
ient mice given immunized Dsg3−/− splenocytes
developed clinical, histological, and immunopatho-
logical phenotypes similar to those of patients with
pemphigus vulgaris.42) This active disease model for
pemphigus vulgaris provides a useful tool to inves-
tigate not only the pathophysiological mechanisms
of blister formation by IgG autoantibodies but also
immunological mechanisms for tolerance of B cells
and T cells to Dsg3.49),50)
Loss of tolerance against desmoglein 3 in both
T and B cells for eﬃcient production
of pathogenic antibodies
Although there is a fundamental diﬀerence
between Dsg3−/− mice and wild-type or Dsg3+/−
mice in their status of tolerance against Dsg3, it was
unknown whether such self-tolerance is acquired by B
cells alone, T cells alone, or both. Therefore,
we attempted to determine whether breakdown of
tolerance at the T-cell level or at the B-cell level or
both is required to produce pathogenic anti-Dsg3
IgG antibodies.49) T and B cells were puriﬁed from
Dsg3−/−, Dsg3+/−, or wild-type mice after immuni-
zation with recombinant Dsg3, combined in various
ways and adoptively transferred into Rag2−/−
recipient mice, and the phenotype in each recipient
mouse was examined. When the recipient mice with
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only those with Dsg3−/− T and Dsg3−/− B cells
showed apparent weight loss.49) Five of eight recip-
ient mice with Dsg3−/− T and Dsg3−/− B cells
showed the weight loss phenotype as well as patchy
hair loss, while none of the other recipient mice with
diﬀerent combinations of T and B cells developed
either weight loss or hair loss. Sera from all ﬁve
recipient mice with the phenotype stained the cell
surface of mouse keratinocytes when added to culture
media. In addition, these ﬁve mice showed IgG
deposition on the keratinocyte cell surface in vivo
and intraepidermal blister formation just above the
basal cell layer in histology.49) These ﬁndings indicate
that loss of tolerance against Dsg3 in T cells as well
as B cells is required for eﬃcient production of
pathogenic anti-Dsg3 IgG antibodies and develop-
ment of the phenotype in our mouse model for
pemphigus. As our model has characteristics similar
to human pemphigus vulgaris, it was also suggested
that tolerance against Dsg3 is established in both
B- and T-cell populations in humans and breakdown
of tolerance in both populations may trigger onset of
the disease.
Isolation and characterization of Dsg3-speciﬁc
T cells from pemphigus model mice
Autoreactive T cells are thought to be involved
in the pathogenesis of pemphigus vulgaris, but
evidence of their direct pathogenicity is lacking.
Recently, Dsg3-speciﬁc CD4+ T cell lines and clones
were isolated from Dsg3−/− mice.51) These Dsg3-
reactive CD4+ T cell clones were adoptively trans-
ferred into Rag2−/−-immunodeﬁcient mice with
primed Dsg3−/− B cells puriﬁed from immunized
Dsg3−/− mice to determine whether all Dsg3-speciﬁc
T cells are able to help B cells to produce pathogenic
antibodies. Dsg3-speciﬁc T cells showed pathogenic
heterogeneity and only 7 of 20 T-cell lines or clones
induced IgG anti-Dsg3 IgG production and the
pemphigus phenotype, while the rest did not.51)
Comparison of the characteristics between patho-
genic and nonpathogenic Dsg3-reactive T-cell clones
led to identiﬁcation of IL-4 and IL-10 as potential
factors associated with pathogenic antibody produc-
tion. Further in vitro analysis showed that IL-4, but
not IL-10, promoted IgG anti-Dsg3 IgG production
by primed B cells.51) In addition, adenoviral expres-
sion of soluble IL-4R, in vivo, but not IL-10R,
or INT-.R1, suppressed anti-Dsg3 IgG production
and the development of the pemphigus phenotype,
indicating the importance of IL4 in this process.51)
Furthermore, single Dsg3-reactive T-cell clones
were demonstrated to help polyclonal naïve B cells to
produce anti-Dsg3 IgG antibodies and induce the
pemphigus phenotype in recipient mice.52) Identiﬁca-
tion and characterization of this pathogenic subpo-
pulation of T cells will provide valuable tools for the
development of eﬃcient therapeutic strategies against
the key “commander” T-cell population that may be
the source of the harmful autoimmune response.
Desmoglein isoforms and skin diseases
Desmoglein exists in four isoforms, Dsg1–Dsg4.
In addition to pemphigus, impetigo, and SSSS
discussed here, the desmogleins are also targeted in
several other skin and heart diseases (Table 1).
Mutations in the Dsg1 gene cause striate palmoplan-
tar keratoderma (MIM 148700), which is an autoso-
mal dominant skin disease characterized by linear
and focal hyperkeratosis of the palms of the hands
and soles of the feet, probably due to haploinsuﬃ-
ciency of Dsg1.53) Mutations in the Dsg4 gene cause
impaired hair-follicle development, which results
Table 1. Desmoglein isoforms and skin diseases that target desmogleins
Isoform Tissue distribution
Skin diseases that target desmogleins
Autoimmune Infection Genetic
Dsg1 Stratiﬁed squamous epithelia PF, PV (MC)
PNP
SSSS
Bullous impetigo
SPPK
Dsg2 All desmosome-bearing epithelia None None ARVC
Dsg3 Stratiﬁed squamous epithelia PV (MD, MC)
PNP
None None
Dsg4 Hair follicle epithelia Cross-reactivity
of anti-Dsg1 IgG
None Inherited hypotrichosis
PF, pemphigus foliaceus; PV, pemphigus vulgaris; MD, mucosal dominant type; MC, mucocutaneous type; PNP, paraneoplastic
pemphigus; SSSS, staphylococcal scalded skin syndrome; SPPK, striate palmoplantar keratoderma; ARVC, Arrhythmogenic right
ventricular cardiomyopathy/dysplasia
M. AMAGAI [Vol. 86, 534in inherited hypotrichosis in humans (e.g., localized
autosomal recessive hypotrichosis) and abnormal
hair with bulbous degenerative changes in lanceolate
hair mice and rats.20) It was initially suggested that
Dsg4 is the autoantigen targeted in pemphigus
vulgaris.20) However, it was subsequently demon-
strated that pemphigus sera show Dsg4 reactivity
due to crossreactivity of a subset of anti-Dsg1 IgG,
and the Dsg4/Dsg1-crossreacting IgG plays no
demonstrable pathogenic role in blister formation.54)
Recently, mutations in the Dsg2 gene were shown to
cause arrhythmogenic right ventricular cardiomyop-
athy/dysplasia, an inherited cardiomyopathy char-
acterized by progressive myocardial atrophy with
ﬁbrofatty replacement.55),56)
Perspective
When we cloned the cDNA for pemphigus
vulgaris antigen in 1991, it was not clear how
desmogleins were involved in other diseases. In the
20 years since then, as molecular mechanisms have
been clariﬁed, desmogleins have been shown to
be involved in many diseases. Further studies of
desmoglein molecules will continue to provide insight
into unsolved pathophysiological mechanisms of
diseases and aid in the development of novel
therapeutic strategies with minimum side eﬀects.
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